Showing results (101-110 of 146) with videos related to

Sort By:
Pageof 15
European Neurology|May 22, 2013
Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapiesClaudio Gobbi, Chiara Zecca, Michael Linnebank, et al.
International Journal of MS Care|January 24, 2014
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis databaseRobert J Fox, Amber R Salter, Tuula Tyry, et al.
Therapeutic Advances in Neurological Disorders|April 29, 2017
Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCEScott D Newsome, Bernd C Kieseier, Shifang Liu, et al.
Infection and Drug Resistance|June 24, 2026
Effect of Early Administration of Casirivimab and Imdevimab in Hospitalized Patients with COVID-19: A Post Hoc AnalysisEleftherios Mylonakis, Amy Sullivan, Selin Somersan-Karakaya, et al.
BMC Public Health|May 13, 2016
Substantial improvements not seen in health behaviors following corner store conversions in two Latino food swampsAlexander N Ortega, Stephanie L Albert, Alec M Chan-Golston, et al.
Neurology|March 6, 2025
Effect of Incident Stroke on Dementia Risk Over 10 Years in a Cohort of Asian American and Non-Latino White Older Adults in CaliforniaL Paloma Rojas-Saunero, Yixuan Zhou, Eleanor Hayes-Larson, et al.
Public Health Nutrition|June 6, 2017
A corner store intervention to improve access to fruits and vegetables in two Latino communitiesStephanie L Albert, Brent A Langellier, Mienah Z Sharif, et al.
Scientific Reports|October 18, 2019
Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with MenRyan R Cook, Jennifer A Fulcher, Nicole H Tobin, et al.
Annals of Neurology|February 5, 2013
Predictors of long-term outcome in multiple sclerosis patients treated with interferon βRobert A Bermel, Xiaojun You, Pamela Foulds, et al.
BMC Neurology|February 11, 2017
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trialDouglas L Arnold, Peter A Calabresi, Bernd C Kieseier, et al.
Pageof 15